Conexeu Sciences Inc.

Conexeu Sciences Inc. is an early-stage medical technology company developing CXU™, a temperature-responsive collagen-based extracellular matrix (ECM) scaffold device candidate in preclinical development for wound care, aesthetics, dentistry, veterinary applications, and 3D bioprinting. Originating from over a decade of University of British Columbia research, the Company acquired exclusive patent rights in the US, EU, Japan, Australia (Canada pending) expiring February 2036, covering ECM scaffold compositions and methods. CXU™ transitions from liquid to gel-like scaffold in approximately 10 minutes at body temperature, evaluated in non-GLP preclinical studies for tissue integration, vascularization, and reduced scarring. The Company plans FDA 510(k) clearance as Class II device for wound care, with no regulatory approvals obtained. Financially, as of January 31, 2026, Conexeu reported $6.3M cash, $6.8M stockholders' equity, but $6.2M accumulated deficit and $1.7M Q1 net loss from R&D, consulting, and salaries amid public transition. This S-1/A registers 9,481,123 common shares (5.3M outstanding, 4.2M from warrants) for resale by securityholders via direct Nasdaq listing (CNXU) without underwriters or proceeds to Company (potential $1.7M from warrant exercises). No revenues generated; dependent on regulatory success and commercialization of sole candidate amid high competition, IP risks, and cash burn. Going public via direct listing enables liquidity for existing holders while funding preclinical-to-clinical transition in $2.6B+ wound care and $11B aesthetics markets.

Key Takeaways